ProQR Therapeutics NV announced encouraging initial safety and pharmacokinetic $(PK)$ data from the first cohort of healthy volunteers in its ongoing Phase 1 trial of AX-0810. The initial results, which showed no safety signals after four weeks of dosing and PK consistent with non-clinical data, support continued dosing in the study. Enrollment and dosing of healthy volunteers are ongoing, with target engagement data expected in the first half of 2026. Additionally, ProQR reported new non-clinical functional proof-of-concept data for AX-2911, which demonstrated over 80% reduction in hepatic fat content in a humanized PNPLA3-148M mouse model, outperforming a clinical-stage PNPLA3-directed antisense therapy. Further details and analyses on AX-2911 will be presented at a later date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158207-en) on January 08, 2026, and is solely responsible for the information contained therein.